Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo Nordisk Pays $1.80bn To Buy Emisphere

Acquires Technology Used For Diabetes Pill Rybelsus

Nov 06 2020

• By Kevin Grogan

Diabetes — Novo Interested In Oral treatments for diabetes • Source: Shutterstock

Related Content

Novo’s Rybelsus Pill Set To Disrupt Europe’s Diabetes Market

Feb 03 2020

Novo Nordisk Enters Its First Strategic RNAi Pact

Nov 19 2019

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

Jan 17 2020

Novo Nordisk Eyes Residual CV Risk In Atherosclerosis With Ziltivekimab

Oct 30 2020

Novo Nordisk's Oral Rybelsus Priced On Par With Injectable GLP-1s, But Big Discounts May Be Needed

Sep 23 2019

Related Companies

Novo Nordisk A/S

Emisphere Technologies, Inc.

Corvidia Therapeutics

Genetix Biotherapeutics

Dicerna Pharmaceuticals, Inc.

Additional Topics

M & A Drug Delivery Technology Commercial Companies Metabolic Disorders BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window